VSTM Verastem Inc.

1.93
+0.09  (+5%)
Previous Close 1.84
Open 1.88
Price To Book 6.66
Market Cap 143,494,842
Shares 74,349,659
Volume 141,423
Short Ratio
Av. Daily Volume 2,858,344
Stock charts supplied by TradingView

NewsSee all news

  1. Verastem Oncology Announces Dosing of First Patient in CSPC's Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma

    Verastem, Inc. (NASDAQ:VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  2. Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766

    Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial Clinical Data Presentation and Regulatory Discussions Planned for 1H 2020 Verastem, Inc. (NASDAQ:VSTM)

  3. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today

  4. Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

    Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial Data Presented Support Potential of Duvelisib Across

  5. Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 presentation at ASH December 7, 2019. ORR 40% in cohort 1 and 62% in cohort 2.
Duvelisib
Peripheral T-Cell Lymphoma (PTCL)
Phase 1/2 initiation of dosing announced January 26, 2017.
Avelumab and defactinib
Ovarian cancer
Phase 1/2 initial data - 21st Congress of European Hematology Association June 9 - 12, 2016
Duvelisib - Conetempo
Treatment-naïve patients with follicular lymphoma
Phase 2 data released June 2016 - short of expectations
Duvelisib (IPI-145) DYNAMO
Indolent non-Hodgkin lymphoma
FDA Approval announced September 24, 2018.
Duvelisib - DUO
Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma
Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015
VS-6063
Mesothelioma prior to surgery
Phase 2 failed to meet endpoint - Jan 2015
Duvelisib (IPI-145)
Rheumatoid arthritis

Latest News

  1. Verastem Oncology Announces Dosing of First Patient in CSPC's Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular Lymphoma

    Verastem, Inc. (NASDAQ:VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  2. Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766

    Combination of Defactinib and CH5126766 Shows Promise in Treating KRAS Mutant Solid Tumors in Clinical Trial Clinical Data Presentation and Regulatory Discussions Planned for 1H 2020 Verastem, Inc. (NASDAQ:VSTM)

  3. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today

  4. Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

    Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial Data Presented Support Potential of Duvelisib Across

  5. Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  6. Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award

    Verastem, Inc. (NASDAQ:VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  7. Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048

    Verastem, Inc. (NASDAQ:VSTM) (the "Company") today announced that it has entered into privately negotiated agreements among the Company and a limited number of investors who are accredited investors (within the meaning

  8. Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

    Results from the Dose Optimization Portion of the Study to be Presented PRIMO Expansion Phase To Investigate Duvelisib 75mg Twice Daily for Two Cycles, Followed by 25mg Twice Daily Four Additional Abstracts

  9. Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress

    Company Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY2019 Revenue Guidance Cash, Cash Equivalents and Short-Term Investments of $160.2 Million as of

  10. Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  11. Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.'s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Verastem, Inc. (NASDAQ:VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  12. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today

  13. Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  14. Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Malignancies

    Duvelisib's Dual Inhibition of PI3K-Delta and PI3K-Gamma Inhibits Migration and Proliferation of Mantle Cell Lymphoma Cells More Effectively Than PI3K-Delta Alone in Preclinical Models Verastem, Inc. (NASDAQ:VSTM)

  15. Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the

  16. Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lymphocytic Leukemia

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,

  17. Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the

  18. Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting

    Verastem, Inc. (NASDAQ:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients,